Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffinic oil - emulsifiable suspension - paraffinic oil petroleum derivative-oil active 821.0 g/l - insecticide - avocado | banana | citrus | custard apple | grape | kiwi fruit | mango | pome fruit | stone fruit | weed control | apple | apric - black scale | black spot - colletotrichum acutatum | bryobia mite | bryobia mite - eggs | carmine mite | cercospora leaf spot | citrus leafminer | cordana leaf spot | european red mite (erm) - eggs | grapevine scale | leaf speckle on banana | oystershell scale | pinkwax scale | powdery mildew | red scale | san jose' scale | scale insects | soft brown scale | tank mixing | white wax scale | additive | agricultural chemical | anthracnose | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | herbicide | minimise antagonism | quadraspidiotus perniciosus | red spider mite | spider mite | spray tank | two-spotted mite | two-spotted spider mite

Австралия - английский - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 46425 - bone matrix implant, animal-derived, bioabsorbable - mastergraft? putty is supplied as a sterile, dry, solid, construct that is hydrated for single patient use and is a mouldable form of bone void filler. mastergraft? products are biocompatible, osteoconductive, porous implants that allows for bony in growth across the graft site while resorbing at a rate consistent with bone healing. mastergraft? putty is intended to help fill voids or gaps in bone, which may be surgically created osseous defects, or osseous defects caused by traumatic injury to the bone. mastergraft? putty provides a bone void filler that is resorbed and is replaced with bone during the natural healing process. the putty when combined with either autogenous bone marrow, and/or sterile water, and/or autograft is indicated as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. additionally, mastergraft putty can be used with autograft as a bone extender. specific indications for use include oral/maxillofacial augmentation or reconstruction.

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffin oil - emulsion - paraffin oil petroleum derivative-oil active 19.46 g/l - insecticide - apple | apricot | citrus | grape | peach | pear | plum | pome fruit | rose | stone fruit | apple | apricot | cherry | delicious - aphid | black scale | citrus leafminer | grapevine scale | mealy bug | oystershell scale | pinkwax scale | red scale | san jose' scale | scale | soft brown scale | spider mite | white wax scale | whitefly | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | mealybug | quadraspidiotus perniciosus

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffin oil - emulsifiable concentrate - paraffin oil petroleum derivative-oil active 811.0 g/l - insecticide - citrus | grape | ornamental (see label) | pome fruit | rose | stone fruit | apple | apricot | cherry | grapefruit | grapevine | - aphid | black scale | citrus leafminer | grapevine scale | mealy bug | oystershell scale | pinkwax scale | red scale | san jose' scale | scale | soft brown scale | spider mite | white wax scale | whitefly | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | mealybug | quadraspidiotus perniciosus

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xorix sdn bhd - salicylic acid -

Малайзия - английский - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

tiger balm (m) sdn bhd - cajuput oil; clove oil; menthol; camphor -

Соединенные Штаты - английский - NLM (National Library of Medicine)

mylan institutional inc. - indapamide (unii: f089i0511l) (indapamide - unii:f089i0511l) - indapamide 2.5 mg - indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see precautions below). diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see precautions below). dependent edema in pregnancy, resulting from restriction of ve

Соединенные Штаты - английский - NLM (National Library of Medicine)

actavis pharma, inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - adapalene 1 mg in 1 g - adapalene and benzoyl peroxide gel 0.1% / 2.5% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. none teratogenic effects: pregnancy category c there are no well-controlled trials in pregnant women treated with adapalene and benzoyl peroxide gel. animal reproduction studies have not been conducted with the combination gel or benzoyl peroxide. furthermore, such studies are not always predictive of human response; therefore, adapalene and benzoyl peroxide gel should be used during pregnancy only if the potential benefit justifies the risk to the fetus. no teratogenic effects were observed in rats treated with oral doses of 0.15 to 5 mg adapalene/kg/day, up to 25 times (mg/m2 /day) the maximum recommended human dose (mrhd) of 2 grams of adapalene and benzoyl peroxide gel. however, teratogenic changes were observed in rats and rabbits when treated with oral doses of greater than or equal to 25 mg adapalene/kg/day representing 123 and 246 times mrhd, respectively. findin

Соединенные Штаты - английский - NLM (National Library of Medicine)

prugen, inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 45 g in 1 g - adapalene gel, 0.1% is indicated for the topical treatment of acne vulgaris. adapalene gel should not be administered to individuals who are hypersensitive to adapalene or any of the components in the vehicle gel.

Соединенные Штаты - английский - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - adapalene (unii: 1l4806j2qf) (adapalene - unii:1l4806j2qf) - adapalene 3 mg in 1 g - adapalene gel, 0.3% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. adapalene gel, 0.3% is contraindicated in patients who have known hypersensitivity to adapalene or any excipient of adapalene gel, 0.3% [see warnings and precautions (5.1)] . risk summary available data from clinical trials with adapalene gel, 0.3% use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of adapalene to pregnant rats and rabbits during organogenesis at dose exposures 40 and 81 times, respectively, the human exposure at the maximum recommended human dose (mrhd) of 2 g resulted in fetal skeletal and visceral malformations (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. data animal data no malformations were observed in rats treated with oral adapalene doses of 0.15 to 5 mg/kg/day, up to 8 times the mrhd based on a mg/m 2 comparison. however, malformations were observed in rats and rabbits when treated with oral doses of ≥ 25 mg/kg/day adapalene (40 and 81 times the mrhd, respectively, based on a mg/m 2 comparison). findings included cleft palate, microphthalmia, encephalocele, and skeletal abnormalities in rats and umbilical hernia, exophthalmos, and kidney and skeletal abnormalities in rabbits. dermal adapalene embryofetal development studies in rats and rabbits at doses up to 6 mg/kg/day (9.7 and 19.5 times the mrhd, respectively, based on a mg/m 2 comparison) exhibited no fetotoxicity and only minimal increases in skeletal variations (supernumerary ribs in both species and delayed ossification in rabbits). risk summary there are no data on the presence of topical adapalene gel or its metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. in animal studies, adapalene is present in rat milk with oral administration of the drug. when a drug is present in animal milk, it is likely that the drug will be present in human milk. it is possible that topical administration of large amounts of adapalene could result in sufficient systemic absorption to produce detectable quantities in human milk (see clinical considerations) . the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for adapalene gel, 0.3% and any potential adverse effects on the breastfed child from adapalene gel, 0.3%, or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breastmilk, use adapalene gel, 0.3% on the smallest area of skin and for the shortest duration possible while breastfeeding. avoid application of adapalene gel, 0.3% to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child. safety and effectiveness have not been established in pediatric patients below the age of 12. clinical studies of adapalene gel, 0.3% did not include subjects 65 years of age and older to determine whether they respond differently than younger subjects. safety and effectiveness in geriatric patients age 65 and above have not been established.